- Trials with a EudraCT protocol (86)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
86 result(s) found for: Rna Vaccine.
Displaying page 1 of 5.
EudraCT Number: 2021-000930-32 | Sponsor Protocol Number: SJ2021005 | Start Date*: 2021-04-27 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 | ||
Medical condition: hemodialysis patients hemodialysis patients with comorbidities | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000633-14 | Sponsor Protocol Number: SZÚ/01591/2021 | Start Date*: 2021-03-30 | |||||||||||
Sponsor Name:Státní zdravotní ústav | |||||||||||||
Full Title: DYNAMICS OF POSTVACCINATION ANTI- SARS-COV-2 ANTIBODY RESPONSE IN EMPLOYES OF THE NATIONAL INSTITUTE OF PUBLIC HEALTH AND VOLUNTARIES 1-2021 | |||||||||||||
Medical condition: antibody response following vaccine application | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001391-42 | Sponsor Protocol Number: Speed-Covid | Start Date*: 2021-05-12 |
Sponsor Name:Medical University of Graz | ||
Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study | ||
Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-002034-37 | Sponsor Protocol Number: IC41-202 | Start Date*: 2006-07-31 |
Sponsor Name:Intercell AG | ||
Full Title: OPEN-LABEL, MULTICENTER TRIAL WITH IC41, A THERAPEUTIC HCV VACCINE IN PATIENTS WITH CHRONIC HCV | ||
Medical condition: chronic Hepatitis C (HCV) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003339-24 | Sponsor Protocol Number: DEN-308 | Start Date*: 2022-12-21 | |||||||||||
Sponsor Name:Takeda Vaccines, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscu... | |||||||||||||
Medical condition: Dengue fever | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007847-28 | Sponsor Protocol Number: DERMA-ER-DC08 | Start Date*: 2011-09-16 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected m... | |||||||||||||
Medical condition: Patients with resected uveal melanoma showing monosomy 3, free of metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000291-11 | Sponsor Protocol Number: IMRES | Start Date*: 2021-05-30 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19) | |||||||||||||
Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004971-30 | Sponsor Protocol Number: FLUGEN-H3N2-V002 | Start Date*: 2018-04-27 | |||||||||||
Sponsor Name:FluGen, Inc | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranas... | |||||||||||||
Medical condition: Prophylactic H3N2(A/Brisbane/10/2007) monovalent influenza vaccine, Bris10 M2SR, for protection against influenza disease caused by seasonal influenza A viruses. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003458-22 | Sponsor Protocol Number: BNT162-17 | Start Date*: 2021-10-04 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Phase II trial to evaluate the safety and immunogenicity of SARS-CoV-2 monovalent and multivalent RNA-based vaccines in healthy subjects | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002818-40 | Sponsor Protocol Number: EHVA_T02/ANRS_VRI07 | Start Date*: 2019-10-25 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000863-22 | Sponsor Protocol Number: 150681 | Start Date*: 2020-06-23 | |||||||||||
Sponsor Name:Thomas Benfield | |||||||||||||
Full Title: Safety and immunogenicity following meningococcal and pneumococcal immunization among adult people living with HIV A single center, non-blinded, randomized clinical trial | |||||||||||||
Medical condition: Immunogenicity following pneumococcal and meningococcal vaccination among people living with HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000260-99 | Sponsor Protocol Number: 10102010 | Start Date*: 2011-04-12 |
Sponsor Name:Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8 | ||
Full Title: Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled Trial | ||
Medical condition: The primary objectives of this study are to: 1. Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one y... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020228-23 | Sponsor Protocol Number: NL32381.000.10 | Start Date*: 2010-12-21 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Immunochemotherapy: Do platin-based chemotherapeutics enhance dendritic cell vaccine efficay in melanoma patients? | ||
Medical condition: Our study population consists of melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node metastasis in whom ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003455-33 | Sponsor Protocol Number: INV-DEN-203 | Start Date*: 2022-12-21 | |||||||||||
Sponsor Name:Takeda Vaccines, Inc. | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteer... | |||||||||||||
Medical condition: Dengue Fever | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001071-23 | Sponsor Protocol Number: DEN-314 | Start Date*: 2018-03-26 | |||||||||||
Sponsor Name:Takeda Vaccines, Inc. | |||||||||||||
Full Title: A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular H... | |||||||||||||
Medical condition: Healthy Volunteers "Vaccination against Dengue Fever and co-administration with Hepatitis A vaccine" | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003102-26 | Sponsor Protocol Number: HIV-CORE007 | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive A... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023946-58 | Sponsor Protocol Number: 2010-023946-58 | Start Date*: 2011-01-31 | |||||||||||
Sponsor Name:ErasmusMC | |||||||||||||
Full Title: Immunogenicity and safety of an adjuvant hepatitis B vaccine (fendrix) compared to Engerix in non-responding HIV-infected patients | |||||||||||||
Medical condition: We want to study the efficacy of Fendrix, a new adjuvant hepatitis B vaccin, in HIV infected patients, who failed to respond on intial standard and subsequent booster Hepatitis b vaccinations. We w... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001512-28 | Sponsor Protocol Number: COVIM | Start Date*: 2021-05-11 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations | |||||||||||||
Medical condition: SARS-CoV-2 immunogenicity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002724-83 | Sponsor Protocol Number: iHIVARNA-01 | Start Date*: 2017-02-22 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral t... | |||||||||||||
Medical condition: Chronic HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.